Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx

Jounce Slashes 57% of Staff, Drops Assets in Stock Merger with Redx

Source: 
BioSpace
snippet: 

One day after revealing a restructuring initiative, Jounce Therapeutics announced it plans to merge its business in an all-stock deal with clinical-stage biotech Redx Pharma.